New in vivo study data!
Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.
Twist Biopharma COVID Antibodies Program
Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity. Several antibodies also show the ability to block S1 binding to ACE2.
We have also developed a set of antibodies targeting the extracellular domain of the ACE2 receptor. These antibodies have high binding affinity and have been demonstrated to inhibit the binding of the S1 protein to ACE2 in vitro.
All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal as potential candidates for both diagnostic and therapeutic uses.
Explore the data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies targeting the S1 protein of SARS-CoV-2
Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.
New in vivo study data!
Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.
Twist Biopharma COVID Antibodies Program
Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity. Several antibodies also show the ability to block S1 binding to ACE2.
We have also developed a set of antibodies targeting the extracellular domain of the ACE2 receptor. These antibodies have high binding affinity and have been demonstrated to inhibit the binding of the S1 protein to ACE2 in vitro.
All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal as potential candidates for both diagnostic and therapeutic uses.
Explore the data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies targeting the S1 protein of SARS-CoV-2
Learn about how Dr. Aaron Sato Twist’s CSO and leader of our Biopharma division is building antibody therapeutics to address COVID-19 infection.
Twist Anti-SARS-CoV-2 S1 Antibodies
Twist Biopharma’s human antibodies that target the SARS-CoV-2 Spike Protein have a potential dual-purpose and could be developed either for virus neutralization or detection in therapeutic and diagnostic applications, respectively.
Binding curves of the antibody clones to SARS-CoV-2 S1 monomer and trimer
Affinity data for individual antibody clones binding of SARS-CoV-2 Spike Glycoprotein S1 or S1 trimer protein. Each clone is indicated with a different color (see legend).
Competition assay
The S1 antibodies were tested in a cell-based S1-ACE2 competition assay to determine if they showed the ability to block the binding of labeled S1 protein to cells expressing the ACE2 receptor. As shown in the figure below, several antibodies block labeled S1 RBD from binding to ACE2 on the Vero cells: TB182-03, TB182-04, TB182-06, TB182-13 and TB181-63
For more information please review the individual antibodies or antibody panel datasheets.
Host Species
HumanSpecies Reactivity
Reacts with Coronavirus SARS-CoV-2Panning Antigen
Recombinant fragment SARS-CoV-2 S1 glycoproteinDatabase Link
MN908947.3Clonality
Recombinant MonoclonalIsotype
Antibodies are human IgG1Purity
>95% by CE-SDSPlate Format
Volume 20 µL/well, Concentration 1 mg/mLTube Format
Volume 100 μL/tube, Concentration 1 mg/mLPanel
| SKU 102895 | $12,500 |
Tube
| TB181-13 | SKU 103103 | $1,000 |
| TB181-03 | SKU 103104 | $1,000 |
| TB181-04 | SKU 103105 | $1,000 |
| TB181-08 | SKU 103106 | $1,000 |
| TB181-63 | SKU 103107 | $1,000 |
| TB182-13 | SKU 103108 | $1,000 |
| TB182-03 | SKU 103109 | $1,000 |
| TB182-04 | SKU 103110 | $1,000 |
| TB182-06 | SKU 103111 | $1,000 |
| TB182-07 | SKU 103112 | $1,000 |
Twist Anti-SARS-CoV-2 S1 Antibodies
Twist Biopharma’s human antibodies that target the SARS-CoV-2 Spike Protein have a potential dual-purpose and could be developed either for virus neutralization or detection in therapeutic and diagnostic applications, respectively.
Binding curves of the antibody clones to SARS-CoV-2 S1 monomer and trimer
Affinity data for individual antibody clones binding of SARS-CoV-2 Spike Glycoprotein S1 or S1 trimer protein. Each clone is indicated with a different color (see legend).
Competition assay
The S1 antibodies were tested in a cell-based S1-ACE2 competition assay to determine if they showed the ability to block the binding of labeled S1 protein to cells expressing the ACE2 receptor. As shown in the figure below, several antibodies block labeled S1 RBD from binding to ACE2 on the Vero cells: TB182-03, TB182-04, TB182-06, TB182-13 and TB181-63
For more information please review the individual antibodies or antibody panel datasheets.
Host Species
HumanSpecies Reactivity
Reacts with Coronavirus SARS-CoV-2Panning Antigen
Recombinant fragment SARS-CoV-2 S1 glycoproteinDatabase Link
MN908947.3Clonality
Recombinant MonoclonalIsotype
Antibodies are human IgG1Purity
>95% by CE-SDSPlate Format
Volume 20 µL/well, Concentration 1 mg/mLTube Format
Volume 100 μL/tube, Concentration 1 mg/mLPanel
| SKU 102895 | $12,500 |
Tube
| TB181-13 | SKU 103103 | $1,000 |
| TB181-03 | SKU 103104 | $1,000 |
| TB181-04 | SKU 103105 | $1,000 |
| TB181-08 | SKU 103106 | $1,000 |
| TB181-63 | SKU 103107 | $1,000 |
| TB182-13 | SKU 103108 | $1,000 |
| TB182-03 | SKU 103109 | $1,000 |
| TB182-04 | SKU 103110 | $1,000 |
| TB182-06 | SKU 103111 | $1,000 |
| TB182-07 | SKU 103112 | $1,000 |
Twist Human Anti-ACE2 Antibodies
The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic applications.
Kinetic Data
The anti-ACE2 antibodies exhibit very high specificity and affinity to their antigen targets with affinities in the picomolar to nanomolar range. The table below lists Fc-capture and direct capture (DC) data from this assay.
Cell Binding Data
The entire panel shows varying degrees of specific binding to VERO E6 cells as shown in the table below, and an example of the flow cytometry data for a single clone is also shown. S1 Fc fusion protein and S1 RBD Fc fusion (expressed in-house) were added as positive controls for ACE2 binding.
Competition Assay
To assess each antibody clone’s ability to interfere with the binding of the S1 protein to ACE2, serial dilutions of ACE2 were added to biotinylated ACE2 protein. The mixture was then added to SARS-CoV-2 S protein RBD immobilized on an ELISA plate and detected with streptavidin-HRP. Background was subtracted from data points prior to log transformation and curve fitting. IC50 values for all antibody clones are presented in the table.
For more information please review the individual antibodies or antibody panel datasheets.
Description
Individual antibody clones that recognize Human ACE2Host Species
HumanSpecies Reactivity
Reacts with Human ACE2Panning Antigen
Recombinant fragment Human ACE2 ECDGene ID
59272Database
NM_001371415Clonality
Recombinant MonoclonalIsotype
IgG antibodies are IgG2 and VHH Fc antibodies are IgG1Purity
>95% by CE-SDSPlate Format
Volume 20 µL/well, Concentration 1 mg/mLTube Format
Volume 100 μL/tube, Concentration 1 mg/mLPanel
| SKU 102896 | $12,500 |
Tube
| TB183-03 | SKU 103091 | $1,000 |
| TB183-05 | SKU 103092 | $1,000 |
| TB183-06 | SKU 103093 | $1,000 |
| TB183-08 | SKU 103094 | $1,000 |
| TB184-111 | SKU 103095 | $1,000 |
| TB184-130 | SKU 103096 | $1,000 |
| TB184-02 | SKU 103097 | $1,000 |
| TB184-04 | SKU 103098 | $1,000 |
| TB184-05 | SKU 103099 | $1,000 |
| TB184-54 | SKU 103100 | $1,000 |
| TB184-07 | SKU 103101 | $1,000 |
| TB184-91 | SKU 103102 | $1,000 |
Twist Human Anti-ACE2 Antibodies
The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic applications.
Kinetic Data
The anti-ACE2 antibodies exhibit very high specificity and affinity to their antigen targets with affinities in the picomolar to nanomolar range. The table below lists Fc-capture and direct capture (DC) data from this assay.
Cell Binding Data
The entire panel shows varying degrees of specific binding to VERO E6 cells as shown in the table below, and an example of the flow cytometry data for a single clone is also shown. S1 Fc fusion protein and S1 RBD Fc fusion (expressed in-house) were added as positive controls for ACE2 binding.
Competition Assay
To assess each antibody clone’s ability to interfere with the binding of the S1 protein to ACE2, serial dilutions of ACE2 were added to biotinylated ACE2 protein. The mixture was then added to SARS-CoV-2 S protein RBD immobilized on an ELISA plate and detected with streptavidin-HRP. Background was subtracted from data points prior to log transformation and curve fitting. IC50 values for all antibody clones are presented in the table.
For more information please review the individual antibodies or antibody panel datasheets.
Panel
| SKU 102896 | $12,500 |
Tube
| TB183-03 | SKU 103091 | $1,000 |
| TB183-05 | SKU 103092 | $1,000 |
| TB183-06 | SKU 103093 | $1,000 |
| TB183-08 | SKU 103094 | $1,000 |
| TB184-111 | SKU 103095 | $1,000 |
| TB184-130 | SKU 103096 | $1,000 |
| TB184-02 | SKU 103097 | $1,000 |
| TB184-04 | SKU 103098 | $1,000 |
| TB184-05 | SKU 103099 | $1,000 |
| TB184-54 | SKU 103100 | $1,000 |
| TB184-07 | SKU 103101 | $1,000 |
| TB184-91 | SKU 103102 | $1,000 |
Description
Individual antibody clones that recognize Human ACE2Host Species
HumanSpecies Reactivity
Reacts with Human ACE2Panning Antigen
Recombinant fragment Human ACE2 ECDGene ID
59272Database
NM_001371415Clonality
Recombinant MonoclonalIsotype
IgG antibodies are IgG2 and VHH Fc antibodies are IgG1Purity
>95% by CE-SDSPlate Format
Volume 20 µL/well, Concentration 1 mg/mLTube Format
Volume 100 μL/tube, Concentration 1 mg/mL
Additional Information
Please contact the Twist Biopharma team here for information regarding additional antibody information,
requesting larger or custom quantities of antibodies or licensing questions.
These products are subject to certain use restrictions set forth in Twist’s Supply Terms and Conditions
and Antibody Supplemental Terms and Conditions.
